Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Half Yearly Report

2 Dec 2013 08:00

RNS Number : 3941U
ViaLogy PLC
02 December 2013
Β 

ο»Ώ

Β 

ViaLogy PLC ("ViaLogy" or "the Company")

Β 

Interim results for the six months ended 30 September 2013

Β 

Β 

Β 

Chairman's statement for the six months ended 30 September 2013

Β 

The Interim Report covers the six-month period to 30 September 2013. The figures show a loss for the period of Β£1,130,356 which includes a non-cash loss of Β£239,627 for amortisation and depreciation. The amortisation charges relate to the value of ViaLogy's Intellectual Property and associated research and development which is amortised over a period of six years. The cash outflow from operations during the period was Β£983,156.

Β 

This six month period in the company's history has been focussed on consolidating ViaLogy's commercial arrangements with existing clients, exploring new business opportunities for QuantumRD and establishing a significant working relationship with one of the biggest and most important companies in the global oil and gas sector, CGG. Among our achievements have been:

Β 

Β· The signing of a Business and Technical Collaboration Agreement with CGG (NYSE: CGG, Euronext: CGG: PA, www.cgg.com) of France, one of the world's largest geosciences companies. It provides ViaLogy with global sales and services locations, access to CGG customers, assistance in scaling ViaLogy's QuantumRD technology to large geographical areas, and specialised high tech data processing to prepare seismic datasets for QuantumRD.

Β· A new contract with our flagship client Chevron (www.chevron.com) expanding ViaLogy's work in the US Delaware Basin. Our task was to precisely map subsurface reservoirs for horizontal drilling that were well below the resolution of 3D seismic. This contract has been successfully completed.

Β· Signing an important contract with a new client, a subsidiary of Singapore-based Gente Oil Global, Pte. Ltd., to apply QuantumRD seismic interpretation technology on Ecuadorian properties in the Oriente Basin. ViaLogy focussed on reservoir discovery, delineation, and development in Napo sandstone formations that have proven too complicated to understand through conventional interpretation. The contract was completed and results were delivered to Gente in September.

During the summer and autumn the Board has also spent a considerable time honing plans for the proposed radical restructuring of ViaLogy. The aim is to position the company so that it can achieve carefully planned technical and commercial expansion whilst maintaining long-term shareholder value.

Β 

Full details of the proposed restructuring can be found in the circular to shareholders dated 18 November 2013. A link to the circular can be found on the company website. A General Meeting has been convened for Wednesday, December 4 2013 to seek shareholder support for the plans. Following the General Meeting it is the intention of the ViaLogy Board to recapitalise ViaLogy which is likely to entail the issue of new equity.

Β 

This is an ambitious and exciting juncture in the company's history and I believe the time has come for the business to benefit from a younger pair of hands on the helm. I have therefore decided to step down as chairman and director of the company at the close of the meeting on the 4th of December. My fellow director, Peter Reynolds, has also decided to resign from the Board at this time to pursue his other business interests. We both take this opportunity to wish ViaLogy every success in the future.Β 

Β 

Β 

Terry Bond

Chairman

ViaLogy PLC

2 December 2013

Β 

Β 

Consolidated income statement for the six months ended 30 September 2013

Β 

Β 

Β 

Unaudited

Unaudited

Audited

Β 

Β 

6 months

6 months

Year to

Β 

Β 

to 30 Sep

to 30 Sep

to 31 Mar

Β 

Notes

2013

2012

2013

Β 

Β 

Β 

Β£

Β£

Β£

Revenue

2

61,569

84,691

257,681

Cost of sales

Β 

126,030

273,115

555,156

Β 

Β 

--------

--------

--------

Gross loss

2

(64,461)

(188,424)

(297,475)

Β 

Β 

Β 

Β 

Β 

Share based payments

Β 

22,748

271,399

528,182

Depreciation and amortisation

Β 

239,627

1,611,829

2,203,657

Other administrative expenses

Β 

803,538

911,814

1,931,708

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Total administrative expenses

Β 

1,065,913

2,795,042

4,663,547

Β 

Β 

--------

--------

--------

Loss from Operations

Β 

(1,130,374)

(2,983,466)

(4,961,022)

Β 

Β 

Β 

Β 

Β 

Finance income

Β 

18

180

2,014

Β 

Β 

--------

--------

--------

Loss for the period / year before taxation

Β 

(1,130,356)

(2,983,286)

(4,959,008)

Β 

Β 

--------

--------

--------

Β 

Β 

Β 

Β 

Β 

Taxation

3

-

144,176

294,822

Β 

Β 

Β 

Β 

Β 

Β 

Β 

--------

--------

--------

Loss for the period / year attributable to equity holders of the parent

Β 

Β 

Β 

Β 

Β 

2

(1,130,356)

(2,839,110)

(4,664,186)

Β 

Β 

--------

--------

--------

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Loss per share

Β 

Β 

Β 

Β 

Basic and diluted

4

(0.109)p

(0.316)p

(0.506)p

Β 

Β 

Consolidated statement of comprehensive income for the six months endedΒ 30 September 2013

Β 

Β 

Β 

Unaudited

Unaudited

Audited

Β 

Β 

6 months

6 months

year to

Β 

Β 

to 30 Sep

to 30 Sep

31 Mar

Β 

Β 

2013

2012

2013

Β 

Β 

Β£

Β£

Β£

Loss after taxation

Β 

(1,130,356)

(2,839,110)

(4,664,186)

Β 

Other comprehensive income

Exchange differences on translating foreign operations

Β 

Β 

Β 

(31,035)

Β 

Β 

(10,759)

Β 

Β 

22,677

Β 

Β 

--------

--------

--------

Total other comprehensive (loss) / income for the period / year

Β 

(31,035)

(10,759)

22,677

Β 

Β 

--------

--------

--------

Total comprehensive loss for the period / year attributable to the equity holders of the parent company

Β 

(1,161,391)

(2,849,869)

(4,641,509)

Β 

Β 

--------

--------

--------

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Consolidated statement of changes in equity for the six months ended 30 September 2013

Β 

Unaudited

Share

Share

Warrant

Foreign

Retained

Total

Β 

capital

premium

reserve

exchange

deficit

Β 

Β 

Β 

Β 

Β 

reserve

Β 

Β 

Β 

β‚€

β‚€

β‚€

β‚€

β‚€

β‚€

Β 

Β 

Β 

Β 

Β 

Β 

Β 

At 1 April 2013

10,391,069

22,733,906

225,000

1,637,611

(32,354,126)

2,633,460

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Total loss for the year

-

-

-

-

(1,130,356)

(1,130,356)

Other comprehensive income

-

-

-

(31,035)

-

(31,035)

Issue of shares

5,333

1,333

-

-

-

6,666

Warrant exercise

-

3,200

(3,200)

-

-

-

Share options expense

-

-

-

-

22,748

22,748

Β 

Β 

Β 

-

Β 

Β 

Β 

Β 

--------

--------

--------

--------

--------

--------

Balance at 30 September 2013

10,396,402

22,738,439

221,800

1,606,576

(33,461,734)

1,501,483

Β 

--------

--------

--------

--------

--------

--------

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Share

Share

Warrant

Foreign

Retained

Total

Β 

capital

premium

reserve

exchange

deficit

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

reserve

Β 

Β 

Β 

β‚€

β‚€

β‚€

β‚€

β‚€

β‚€

Β 

Β 

Β 

Β 

Β 

Β 

Β 

At 1 April 2012

8,519,551

21,475,505

-

1,614,934

(28,218,122)

3,391,868

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Total loss for the year

-

-

-

-

(4,664,186)

(4,664,186)

Other comprehensive income

-

-

-

22,677

-

22,677

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Issue of shares

1,871,518

1,363,151

-

-

-

3,234,669

Share issue expenses

-

(104,750)

-

-

-

(104,750)

Share options expense

-

-

-

-

528,182

528,182

Issue of warrants

-

-

225,000

-

-

225,000

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

--------

--------

--------

--------

--------

--------

Balance at 31 March 2013

10,391,069

22,733,906

225,000

1,637,611

(32,354,126)

2,633,460

Β 

--------

--------

--------

--------

--------

--------

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Consolidated statement of financial position at 30 September 2013

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Unaudited

Unaudited

Audited

Β 

Β 

30 Sep

30 Sep

31 Mar

Β 

Β 

2013

2012

2013

Β 

Notes

Β£

Β£

Β£

Assets

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Non-current assets

Β 

Β 

Β 

Β 

Property, plant and equipment

Β 

328,496

374,268

359,165

Intangible assets

Β 

882,087

1,390,785

1,022,054

Β 

Β 

Β 

Β 

Β 

Β 

Β 

--------

--------

--------

Β 

Β 

1,210,583

1,765,053

1,381,219

Β 

Β 

--------

--------

--------

Current assets

Β 

Β 

Β 

Β 

Trade and other receivables

Β 

107,799

180,288

153,876

Cash and cash equivalents

Β 

307,047

1,150,073

1,304,729

Β 

Β 

--------

--------

--------

Β 

Β 

414,846

1,330,361

1,458,605

Β 

Β 

--------

--------

--------

Total Assets

2

1,625,429

3,095,414

2,839,824

Β 

Β 

--------

--------

--------

Liabilities

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Current liabilities

Β 

Β 

Β 

Β 

Trade and other payables

Β 

123,946

138,010

206,364

Β 

Β 

Β 

Β 

Β 

Non-current liabilities

Β 

Β 

Β 

Β 

Deferred tax liability

3

-

141,037

-

Β 

Β 

--------

--------

--------

Total liabilities

2

123,946

279,047

206,364

Β 

Β 

Β 

Β 

Β 

Capital and reserves attributable to equity

Β 

Β 

Β 

Β 

holders of the Company

Β 

Β 

Β 

Β 

Share capital

Β 

10,396,402

9,266,069

10,391,069

Share premium

Β 

22,738,439

22,731,956

22,733,906

Warrant reserve

Β 

221,800

-

225,000

Foreign exchange reserve

Β 

1,606,576

1,604,175

1,637,611

Retained deficit

Β 

(33,461,734)

(30,785,833)

(32,354,126)

Β 

Β 

--------

--------

--------

Shareholders' funds

Β 

1,501,483

2,816,367

2,633,460

Β 

Β 

--------

--------

--------

Total equity and liabilities

Β 

1,625,429

3,095,414

2,839,824

Β 

Β 

--------

--------

--------

Consolidated statement of cash flows for six months ended 30 September 2013

Β 

Β 

Β 

Unaudited

Unaudited

Audited

Β 

Β 

30 Sep

30 Sep

31 Mar

Β 

Β 

2013

2012

2013

Β 

Β 

Β£

Β£

Β£

Cash flows from operating activities

Β 

Β 

Β 

Β 

Loss from operations before tax

Β 

(1,130,356)

(2,983,286)

(4,959,008)

Β 

Β 

Β 

Β 

Β 

Adjustments for :-

Β 

Β 

Β 

Β 

Finance income

Β 

(18)

(180)

(2,014)

Depreciation

Β 

26,989

36,640

77,273

Amortisation

Β 

212,638

1,575,189

2,216,384

Share option expense

Β 

22,748

271,399

528,183

Foreign exchange movements

Β 

4,201

12,729

22,677

Director's fees prepaid

Β 

-

82,968

27,656

Β 

Β 

--------

--------

--------

Cashflows used in operating activities before changes in working capital

Β 

(863,798)

(1,004,541)

(2,178,849)

Β 

Β 

Β 

Β 

Β 

Decrease / (increase) in trade and other receivables

Β 

46,077

(106,125)

3,255

Β (Decrease) / increase in trade and other payables

Β 

(82,418)

(66,498)

1,856

Β 

Β 

Β 

Β 

Β 

Β 

Β 

--------

--------

--------

Net cash flows used in operating activities

Β 

(900,139)

(1,177,164)

(2,173,738)

Β 

Β 

Β 

Β 

Β 

Investing activities

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Internally generated intangible asset

Β 

(84,985)

(191,671)

(341,222)

Purchase of property, plant and equipment

Β 

(4,680)

(21,284)

(25,361)

Interest received

Β 

18

180

2,014

Β 

Β 

--------

--------

--------

Β 

Β 

(89,683)

(212,775)

(364,569)

Cash flows from financing activities

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Cash inflow from issue of new shares

Β 

-

2,045,000

3,459,669

Share issue costs

Β 

-

(50,450)

(104,750)

Cash inflow from exercise of options and warrants

Β 

6,666

8,419

-

Β 

Β 

--------

--------

--------

Β 

Β 

6,666

2,002,969

3,354,919

Β 

Β 

Β 

Β 

Β 

(Decrease) / increase in cash and cash equivalents

Β 

(983,156)

613,030

816,612

Β 

Β 

Β 

Β 

Β 

Foreign exchange differences on translation of cash and cash equivalents.

Β 

(14,526)

(18,324)

(67,250)

Cash and cash equivalents at beginning of period /year

Β 

1,304,729

555,367

555,367

Β 

Β 

--------

--------

--------

Β 

Β 

Β 

Β 

Β 

Cash and cash equivalents at end of period / year

Β 

307,047

1,150,073

1,304,729

Β 

Β 

--------

--------

--------

Β 

Β 

Β 

Notes forming part of the unaudited consolidated accounts for the six months ended 30 September 2013

Β 

1 Accounting policies

Basis of preparation

The interim financial information has been prepared using policies based on International Financial Reporting Standards (IFRS and IFRIC interpretations) issued by the International Accounting Standards Board ("IASB") as adopted for use in the EU. The interim financial information has been prepared using the accounting policies which will be applied in the Group's statutory financial information for the year ended 31 March 2014.

Β 

The interim financial information for the period 1 April 2013 to 30 September 2013 is unaudited. In the opinion of the Directors the interim financial information for the period presents fairly the financial position, results from operations and cash flows for the period in conformity with the generally accepted accounting principles consistently applied. The interim financial information incorporates comparative figures for the interim period 1 April 2012 to 30 September 2012 and the audited financial year to 31 March 2013.The financial information contained in this interim report does not constitute statutory accounts as defined by section 435 of the Companies Act 2006. The comparatives for the full year ended 31 March 2013 are not the Company's full statutory accounts for that year. A copy of the statutory accounts for that year has been delivered to the Registrar of Companies. The auditor's report on those accounts was unqualified, but did include references to any matters to which the auditor drew attention by way of emphasis in respect of going concern, without qualifying their report and did not contain a statement under section 498(2)-(3) of the Companies Act 2006.

Β 

Going concern

Β 

As noted in the circular send to shareholders on 18 November 2013 for the General Meeting on 4th December 2013, the Board are proposing to restructure the company. The net result of the restructuring will be that working capital requirements will be greatly reduced from 1 January 2014. Following the General Meeting, it is the intention of the newly constituted ViaLogy Board to recapitalise ViaLogy which is likely to entail the issue of new equity. Whilst the Directors are confident that additional funding can be raised to meet the Group's development and working capital needs, and the Group has been successful in the past in this regard, a significant uncertainty exists given the absence of committed funding at the date of approval of these financial statements.

Β 

The financial statements do not include the adjustments that would result if the Group was unable to continue as a going concern.

Β 

2 Segmental analysis

The Group has two reportable segments:

Β· Head office - this segment is the head office of the Group.

Β· Operations - this segment is involved in sales and technology development in the USA.

The operating results of these segments are regularly reviewed by the Group's chief operating decision maker in order to make decisions about the allocation of resources and assess their performance.

30 September 2013 Reportable segment analysis - unaudited

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Operations

Head Office

Consolidated

Β 

Β 

Β£

Β£

Β£

Revenue from external customers

Β 

61,569

-

61,569

Β 

Β 

--------

--------

--------

Gross loss

Β 

(64,461)

-

(64,461)

Finance income

Β 

-

18

18

Β 

Β 

--------

--------

--------

Loss for the period after taxation

Β 

(944,221)

(186,135)

(1,130,356)

Segment assets

Β 

1,304,037

321,392

1,625,429

Segment liabilities

Β 

44,332

79,614

123,946

Β 

Β 

--------

--------

--------

Costs to acquire plant, property and equipment

Β 

4,680

-

4,680

Costs to acquire intangible assets

Β 

84,985

-

84,985

Depreciation and amortisation

Β 

239,477

150

239,627

Share based payments

Β 

18,364

4,384

22,748

Β 

Β 

--------

--------

--------

Β 

Β 

Β 

Β 

Β 

Year ended 31 March 2013 Reportable segment analysis - audited

Β 

Β 

Operations

Head Office

Consolidated

Β 

Β 

Β£

Β£

Β£

Revenue from external customers

Β 

257,681

-

257,681

Β 

Β 

--------

--------

--------

Gross loss

Β 

(297,475)

-

(297,475)

Finance income

Β 

-

2,014

2,014

Tax credit

Β 

294,822

-

294,822

Β 

Β 

--------

--------

--------

Loss for the year after taxation

Β 

(4,028,262)

(635,924)

(4,664,186)

Β 

Β 

Β 

Β 

Β 

Segment assets

Β 

1,559,043

1,280,781

2,839,824

Segment liabilities

Β 

128,012

78,352

206,364

Β 

Β 

--------

--------

--------

Costs to acquire plant, property and equipment

Β 

42,309

(16,948)

25,361

Costs to acquire intangible assets

Β 

341,222

-

341,222

Depreciation and amortisation

Β 

2,196,101

7,556

2,203,657

Share based payments charged

Β 

451,056

77,126

528,182

Β 

Β 

--------

--------

--------

Β 

Β 

Β 

Β 

Β 

All material non-current assets are owned by the USA subsidiary and are located in the USA.

3 Deferred Tax

Β 

Β 

Β 

Unaudited

Unaudited

Β 

Β 

Β 

Period to

Period to

Β 

Β 

Β 

30 September

30 September

Β 

Β 

Β 

2013

2012

Β 

Β 

Β 

Β£

Β£

Β 

Β 

Β 

Β 

Β 

At 1 April

Β 

Β 

-

285,242

Β 

Β 

Β 

Β 

Β 

Credit to the income statement for the six months to 30 September

Β 

Β 

-

(144,176)

Foreign exchange translation

Β 

Β 

-

(29)

Β 

Β 

Β 

--------

--------

At 30 September

Β 

Β 

-

141,037

Β 

Β 

Β 

--------

--------

Β 

Β 

Β 

Β 

Β 

Audited

Β 

Β 

Β 

Β 

Year ended

Β 

Β 

Β 

Β 

31 March 2013

Β 

Β 

Β 

Β 

Β£

Β 

Β 

Β 

Β 

Β 

Β 

At 1 April

Β 

Β 

285,242

Β 

Β 

Β 

Β 

Β 

Β 

Credit to the income statement for the year

Β 

Β 

(294,822)

Β 

Foreign exchange translation

Β 

Β 

9,580

Β 

Β 

Β 

Β 

--------

Β 

At 31 March

Β 

Β 

-

Β 

Β 

Β 

Β 

--------

Β 

Β 

Deferred tax is calculated in full on temporary differences under the liability method using a tax rate of 35%.

Β 

4 Loss per share

Basic

Β 

The calculation of loss per share is based on the loss for the period of Β£1,130,356 (2012 - loss Β£2,839,110, full year loss Β£4,664,186) and on 1,039,523,650, (2012 - 899,549,947, 2012 full year - 921,224,058) ordinary shares, being the weighted average number of ordinary shares in issue during the period.

Β 

Diluted

Β 

Diluted loss per share dilutes the basic loss per share to take into account share options and warrants. The calculation includes the weighted average number of ordinary shares that would have been issued on the conversion of all the dilutive share options and warrants into ordinary shares. 33,890,242 options (2012 - 106,020,272 options, 2012 full year 125,535,913 options) have been excluded from this calculation as this would reduce the loss per share.

Β 

5 Share capital -unaudited

Β 

Allotted, called up and fully paid

Β 

2013

2012

2013

2012

Β 

Number

Number

Β£

Β£

Ordinary Shares of 1p each

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

At 1 AprilΒ 

1,039,106,911

851,955,130

10,391,069

8,519,551

Shares issued

-

74,363,637

-

743,637

Employee share options exercised

-

288,144

-

2,881

Warrants exercised

533,333

-

5,333

-

Β 

Β 

--------

--------

--------

--------

At 30 September

1,039,640,244

929,606,911

10,396,402

9,266,069

Β 

Β 

Β 

Β 

__________

__________

__________

__________

Β 

Year Ended 31 March 2013 Share capital - audited

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Allotted, called up and fully paid

Β 

Β 

2013

2012

2013

2012

Β 

Β 

Number

Number

Β£

Β£

Β 

Ordinary shares of 1p each

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

At 1 April

851,955,130

734,102,725

8,519,551

7,341,027

Β 

Shares issued

187,151,781

117,852,405

1,871,518

1,178,524

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

--------

--------

--------

--------

Β 

At 31 March

1,039,106,911

851,955,130

10,391,069

8,519,551

Β 

Β 

__________

__________

__________

__________

6 Post Reporting date events

There are no post reporting date events.

Β 

For further information:

Β 

ViaLogy PLC

Terry Bond, Chairman - UK & Europe +44 (0) 1235 834 734

Β 

Nominated Advisor to ViaLogy PLC (Cantor Fitzgerald Europe)

Mark Percy / Catherine Leftley - Corporate Finance +44 (0) 207 894 7000

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
IR EAXAAELKDFEF
Date   Source Headline
15th May 20187:00 amRNSYear-end Trading Update and £2.5m Fundraising
30th Apr 20184:00 pmRNSNotice of Trading Update
29th Mar 20187:00 amRNSPremaitha to attend industry conferences in APAC
26th Mar 20187:00 amRNSUpdate on UK patent infringement claim
16th Feb 20187:00 amRNSPremaitha secures market entry into Egypt
14th Feb 201810:25 amRNSHolding(s) in Company
12th Feb 20187:00 amRNSThermo Fisher - issue of warrants
6th Feb 20187:00 amRNSPremaitha to attend key conferences in Middle East
5th Feb 20187:00 amRNSPremaitha's IONA test approved for sale in Brazil
24th Jan 20187:00 amRNSUK High Court grants right to appeal
22nd Jan 20187:00 amRNSSecured loan facility agreement with Thermo Fisher
29th Dec 20177:00 amRNSHalf Year Results
11th Dec 20177:00 amRNSPremaitha secures four further laboratories in EU
1st Dec 20179:40 amRNSPremaitha CEO Wins Outstanding Contribution Award
27th Nov 20177:00 amRNSMiddle East laboratory network expansion
23rd Nov 20177:00 amRNSPremaitha signs new partner in East Asia
21st Nov 201710:47 amRNSLitigation First Instance Judgment
30th Oct 201710:08 amRNSGrant of Share Options
24th Oct 20173:45 pmRNSResult of AGM
24th Oct 20177:00 amRNSAGM Statement
13th Oct 20177:00 amRNSMiddle East Update
29th Sep 20177:04 amRNSFinal Results
29th Sep 20177:01 amRNSNotice of AGM
21st Sep 20174:05 pmRNSHolding(s) in Company
19th Sep 20177:00 amRNSPremaitha to offer NIPT in South Africa
7th Sep 20173:10 pmRNSFurther Patent Infringement Claims
29th Aug 20177:00 amRNSApproved for Good Manufacturing Process in Brazil
18th Jul 20172:02 pmRNSHolding(s) in Company
12th Jul 20177:00 amRNSInvestment Agreement Extension with Thermo Fisher
10th Jul 20177:00 amRNSPremaitha announces two laboratory hub contracts
3rd Jul 20177:00 amRNSLitigation Update
27th Jun 20177:00 amRNSHolding(s) in Company
16th Jun 20177:00 amRNSPremaitha launches Sage NIPT solution
5th Jun 20177:00 amRNSIndia Business Update
26th May 20177:00 amRNSIONA test validation on Thermo Fisher's Ion S5
19th May 20172:30 pmRNSPremaitha welcomes NIPT recommendation in France
16th May 20177:00 amRNSYear End Trading Update
12th May 20172:15 pmRNSUpdate Re. Swiss Customer
3rd Apr 20174:48 pmRNSHolding(s) in Company
31st Mar 20174:00 pmRNSSecond tranche of warrants issued to Thermo Fisher
17th Mar 20177:15 amRNSHardman Research: Expanding global distribution
13th Mar 20177:00 amRNSPremaitha to Attend International Medical Events
2nd Mar 201711:03 amRNSCompletion of Yourgene Acquisition
27th Feb 20177:00 amRNSCompletion of Acquisition
22nd Feb 20179:37 amRNSHolding(s) in Company
20th Feb 20177:00 amRNSMiddle East Business Update
16th Feb 20175:34 pmRNSHolding(s) in Company
15th Feb 20177:00 amRNSIssue of Equity
14th Feb 20179:32 amRNSHolding(s) in Company
13th Feb 20177:00 amRNSNew partnership with European diagnostics group

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.